Finding · criterion S5
Does a peptide certificate of analysis prove sterility?
A purity result does not establish sterility. A certificate supports only the tests performed on the identified sample, using the stated methods.
Read the test name before the percentage
A prominent purity percentage can dominate a seller page while leaving the important question unanswered: what was measured? Identity, purity, amount of active ingredient, sterility, and bacterial endotoxins describe different properties. A report needs an explicit result for the property being claimed.
FDA manufacturing guidance treats sterility and endotoxin control as distinct concerns. Removing microbes does not necessarily remove endotoxins. The presence of a chemical purity result therefore supplies no missing microbial result. This distinction matters when a storefront presents one laboratory document as evidence for every quality claim.
Match the report to the material
The useful identifiers are the sample name, lot or batch number, submitting party, laboratory, and testing date. A product name alone cannot connect a report to every vial sold under that name. An older certificate may describe a different batch, and a report for raw material may not describe the finished product.
The seller should make that connection understandable. A downloadable file with clear identifiers is more informative than an undated graphic. A laboratory logo or a sentence saying third-party tested supplies less evidence than the report itself. These are documentation distinctions, not independent proof that a sample was representative.
Ask how the tested sample was selected
A named lot connects a report to a batch identifier, but it does not explain how the submitted sample was selected. FDA manufacturing guidance describes scientifically sound sampling plans that produce representative samples. A vendor-selected vial, an independently collected sample and a raw-material sample are different evidence situations.
Look for an explanation of the material tested, the sampling party and the link to the finished product. If that information is absent, the report can still describe its submitted sample, but the missing sampling history limits broader claims about every unit. A laboratory’s identity alone cannot fill that gap.
Read the method and the reporting limit
FDA’s Q2(R2) analytical-validation guidance treats fitness for the intended purpose as central. The appropriate method depends on what is being measured. A technique that supports an identity claim does not automatically answer a question about the amount of an impurity, microbial contamination or the amount of active ingredient.
The guidance also distinguishes detection from quantitation. A method may detect a substance below the level at which it can reliably report an amount. A not-detected result should therefore be read alongside the stated method and detection limit; it is not a claim of absolute zero. A result below a quantitation limit is different again.
If a certificate shows only pass or a purity percentage, ask which tests, units and acceptance criteria support it. Two reports cannot be meaningfully compared solely by choosing the larger percentage when the methods or properties measured differ. These questions help interpret a document; they do not independently validate the laboratory or authorize human use.
Separate a document from a product decision
Even a genuine report has limits. It describes the submitted sample under particular methods and conditions. It does not establish how every unit was filled, transported, or stored. It also does not turn a research product into an approved medicine or establish suitability for human use.
Peptide Alliance records whether a reachable analytical document exists under S5. Passing that disclosure check does not certify sterility, authenticate every lot, or override the separate questions about a prescriber and a filling pharmacy. Reading those criteria together prevents one impressive percentage from standing in for the entire supply chain.
Related standard: S5. Analytical documentation. Evidence for individual companies appears in the seller ledger.
Related reading
Sources
- FDA: Q2(R2) analytical procedure validation
- FDA: representative sampling and component controls
- FDA: sterile drug products produced by aseptic processing
- FDA: production and process controls questions and answers
Related findings
What should a seller disclose about cold shipping?A shipping promise should identify storage instructions, the responsible pharmacy, and the route for resolving a temperature concern. Delivery speed alone cannot establish product quality.
Which laboratories sign the research vendors' test reports?A handful of laboratories sign most of the reports, few of them state an accreditation on their own sites, and some vendors credit a laboratory on the homepage that signs none of their documents.
The state of the Standard, edition 1Eight criteria applied to every record, each reported as its own pass, fail and not-verified count, split between telehealth services and research vendors. No criterion is summed with another, and no record is scored.
The criterion the licensed services fail and the research vendors passAlmost the whole split runs one way. The sellers operating outside the prescription system publish more laboratory evidence than the licensed services do, with exceptions on both sides named on the page. The split is structural rather than a difference in care, and a certificate is a document about one lot, not an approval.